Ambulatory disabilities and the use of walking aids in patients with Hereditary Motor and Sensory Neuropathy type i (HMSN I)

Disability and Rehabilitation: Assistive Technology

Volumn 2, Issue 1, 2007, Pages 35-41

  Van Der Linden, Marleen H ^a   Kalkman, Joke S ^b   Hendricks, Henk T ^a   Schillings, Maartje L ^b   Zwarts, MacHiel J ^b   Bleijenberg, Gijs ^b   Van Engelen, Baziel G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Institute of Neurology   (Netherlands)

Author keywords

disability evaluation; Hereditary motor and sensory neuropathies; mobility limitation; motor activity; quality of life; sickness impact profile

Indexed keywords

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DISABILITY; DISABLED PERSON; FEMALE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MALE; MIDDLE AGED; ORTHOPEDIC EQUIPMENT; SOCIOECONOMICS; UTILIZATION REVIEW;

ADULT; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; DISABLED PERSONS; FEMALE; HEREDITARY MOTOR AND SENSORY NEUROPATHIES; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC EQUIPMENT; SOCIOECONOMIC FACTORS;

EID: 62749100565     PISSN: 17483107     EISSN: 17483115     Source Type: Journal    
DOI: 10.1080/17483100600995086     Document Type: Article

References (25)

1. Martini R, Berciano J, Van Broeckhoven C. 5th Workshop of the European CMT Consortium, 69th ENMC International Workshop: therapeutic approaches in CMT neuropathies and related disorders 23-25 April 1999, Soestduinen, The Netherlands. Neuromuscul Disord 2000;10(1):69-74. (Pubitemid 30006868)
2. Gabreëls-Festen AA, Bolhuis PA, Hoogendijk JE, Valentijn LJ, Eshuis EJ, Gabreëls FJ. Charcot-Marie-Tooth disease type 1A: morphological phenotype of the 17p duplication versus PMP22 point mutations. Acta Neuropathol (Berl) 1995;90(6):645-649.
3. Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000;123(7):1516-1527. (Pubitemid 30420950)
4. Garcia A, Combarros O, Calleja J, Berciano J. Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhood: a longitudinal clinical and electrophysiologic study. Neurology 1998;50(4):1061-1067. (Pubitemid 28212838)
5. Berciano J, Garcia A, Combarros O. Initial semeiology in children with Charcot-Marie-Tooth disease 1A duplication. Muscle Nerve 2003;27(1):34-39. (Pubitemid 36083441)
6. Birouk N, Gouider R, Le Guern E, et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 1997;120(5):813-823. (Pubitemid 27222986)
7. Thomas PK, MarquesW Jr, Davis MB, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997;120:465-478. (Pubitemid 27153639)
8. Vinci P, Perelli SL. Footdrop, foot rotation, and plantarflexor failure in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil 2002;83(4):513-516. (Pubitemid 34275233)
9. Holmberg BH. Charcot-Marie-Tooth disease in northern Sweden: an epidemiological and clinical study. Acta Neurol Scand 1993;87(5):416-422. (Pubitemid 23171058)
10. Fowler WM, Abresch RT, Koch TR, Brewer ML, Bowden RK, Wanlass RL. Employment profiles in neuromuscular diseases. Am J Phys Med Rehabil 1997;76(1):26-37. (Pubitemid 27091866)
11. Pfeiffer G, Wicklein EM, Ratusinski T, Schmitt L, Kunze K. Disability and quality of life in Charcot-Marie-Tooth disease type 1. J Neurol Neurosurg Psychiatry 2001;70(4):548-550. (Pubitemid 32269700)
12. MacMillan JC, Harper PS. The Charcot-Marie-Tooth syndrome: perceptions of disability and projected use of DNA diagnostic tests. Clin Genet 1992;42(4):161-163.
13. Teunissen LL, Eurelings M, Notermans NC, Hop JW, van Gijn J. Quality of life in patients with axonal polyneuropathy. J Neurol 2000;247(3):195-199. (Pubitemid 30189401)
14. Molenaar DSM, Vermuelen M, de Visser M, de Haan R. Impact of neurologic signs and symptoms on functional status in peripheral neuropathies. Neurology 1999;52(1):151-156. (Pubitemid 29044414)
15. Piccininni M, Falsini C, Pizzi A. Quality of life in hereditary neuromuscular diseases. Acta Neurol Scand 2004;109(2): 113-119. (Pubitemid 38175050)
16. Medical Research Council. Aids to the examination of the peripheral nerve injuries. London: Her Majesty's Stationery Office; 1981. p 1.
17. Jacobs HM, Luttik A, Touw-Otten FW, de Melker RA. The sickness impact profile; results of an evaluation study of the Dutch version. Ned Tijdschr Geneeskd 1990;134(40):1950-1954. (Pubitemid 20330025)
18. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19(8):787-805. (Pubitemid 11021288)
19. van der Werf SP, Prins JB, Vercoulen JH, van der Meer JW, Bleijenberg G. Identifying physical activity patterns in chronic fatigue syndrome using actigraphic assessment. J Psychosom Res 2000;49(5):373-379. (Pubitemid 32123814)
20. Brooks R. EuroQol: the current state of play. Health Policy 1996;37(1):53-72. (Pubitemid 26191458)
21. de Boer AGEM, van Lanschot JJB, Stalmeier PFM, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res 2004;13:311-320.
22. Vercoulen JH, Swanink CM, Fennis JF, et al. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994;38:383-392. (Pubitemid 24188056)
23. Vercoulen JH, Alberts M, Bleijenberg G. De checklist individual strength (CIS) [the checklist individual strength]. Gedragstherapie 1999;32:131-136.
24. Servaes P, Verhagen CA, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. Cancer 2002;95(9):2017-2026. (Pubitemid 35222183)
25. Kalkman JS, Schilling ML, van der Werf SP, Padberg GW, Zwarts MJ, van Engelen BGM, Bleijenberg G. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I patients. J Neurol Neurosurg Psychiatry 2005; 76:1406-1409. (Pubitemid 41360981)